These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19458053)

  • 1. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population.
    Wu W; Zhang W; Qiao R; Chen D; Wang H; Wang Y; Zhang S; Gao G; Gu A; Shen J; Qian J; Fan W; Jin L; Han B; Lu D
    Clin Cancer Res; 2009 Jun; 15(11):3889-95. PubMed ID: 19458053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
    Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
    PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
    Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
    Nairuz T; Bushra YU; Kabir Y
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
    Li Y; Huang XE; Jin GF; Shen HB; Xu L
    Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population.
    Du Y; He Y; Mei Z; Qian L; Shi J; Jie Z
    Clin Respir J; 2016 May; 10(3):311-7. PubMed ID: 25308691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P; Wang YD; Cheng J; Chen JC; Ha MW
    Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
    Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
    Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients.
    Wang L; Wang LL; Shang D; Yin SJ; Sun LL; Wang XY; Ji HB
    Kaohsiung J Med Sci; 2019 Jan; 35(1):39-48. PubMed ID: 30844146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
    Qiu M; Yang X; Hu J; Ding X; Jiang F; Yin R; Xu L
    PLoS One; 2013; 8(8):e72251. PubMed ID: 23977265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
    Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
    Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
    Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
    PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.